Clinical Trials
4
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)A Prognostic Study for Patients With Cardiovascular Disease in Niigata
- Conditions
- Cardiovascular DiseasesHeart Failure
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Niigata University Medical & Dental Hospital
- Target Recruit Count
- 8500
- Registration Number
- NCT06992284
- Locations
- 🇯🇵
Niigata University, Niigata, Japan
Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Ovarian Squamous Cell Carcinoma
- Interventions
- Drug: MK-3475 (pembrolizumab)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Niigata University Medical & Dental Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT05737199
- Locations
- 🇯🇵
Niigata University Medical & Dental Hosptal, Niigata, Niigata, Japan
SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Niigata University Medical & Dental Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT02840708
- Locations
- 🇯🇵
Niigata University Med & Dental Hospital, Niigata, Japan
Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan
Phase 2
Completed
- Conditions
- Pulmonary Alveolar Proteinosis, Autoimmune
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2019-02-07
- Lead Sponsor
- Niigata University Medical & Dental Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT02835742
- Locations
- 🇯🇵
Niigata University Med & Dental Hospital, Niigata, Japan
News
No news found